Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sharaz Shafait
Observed institutions:
AstraZeneca (United Kingdom),
BC Cancer Agency,
University of British Columbia,
Vancouver General Hospital,
Vancouver Prostate Centre
OpenAlex ID:
A5000960648
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2010
·
Ursula Kortmann
, Jessica N. McAlpine
, et al.
·
Clinical Cancer Research
·
70
PDF
Data from Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023
·
Ursula Kortmann
, Jessica N. McAlpine
, et al.
Data from Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023
·
Ursula Kortmann
, Jessica N. McAlpine
, et al.
Supplementary Figure S1 from Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023
·
Ursula Kortmann
, Jessica N. McAlpine
, et al.
PDF
Supplementary Figure S1 from Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023
·
Ursula Kortmann
, Jessica N. McAlpine
, et al.
Show more works
View as search
Works count:
5
Citation count:
70
H-index:
1
I10-index:
1
Year
Topic
Type
